While BRAF-MEK inhibition is not a solution for all PCPs, this targeted therapy suggests a reliable adjuvant therapy for tumor regression that avoids the surrounding tissue damage characteristic of current treatment approaches. Here, MAP2K7 is linked to neoplasm.